A Closer Look at the Clinical, Economic and Developmental Impact of Alopecia Areata: Strategies to Improve Patient Adherence, Quality of Life, and Costs

A continuing medical education activity provided by NAMCP and AAMCN

Preparing for a New Era in Alopecia Areata Management: Managed Care Considerations
on the Role of New and Emerging Therapies is a three-part webinar series

This is Part 3 of the series focusing on strategies to improve patient adherence,
quality of life, and costs in alopecia areata

This activity is an archive from the webinar held March 31, 2021

This activity is valid from April 1, 2021 to April 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Pfizer

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body. People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. More than half of patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety. Fortunately for patients with this disease, several new treatments are currently undergoing late stage clinical trials, including JAK inhibitors and combinations, that have shown improved efficacy and safety.

Upon completion of this activity, participants will be able to:

  • Explore challenges to patient adherence and quality of life in alopecia areata (AA)

  • Discuss strategies to implement JAK inhibitors into the treatment paradigm as they are approved, especially as it relates to patient adherence and quality of life

  • Assess how different biomarkers, comorbidities and adherence barriers play a role in long-term treatment decision making for patients with AA

  • Review recent clinical trial information around the efficacy and safety of emerging JAK inhibitors currently undergoing clinical studies in AA and their effect on patient quality of lifeTransform therapeutic advances and resource utilization data on emerging therapies in alopecia areata into informed health plan decisions and formulary discussions


Faculty: Seth J. Orlow, MD, PhD
Chair, The Ronald O. Perelman Department of Dermatology
NYU Grossman School of Medicine


Dr. Orlow has no disclosures relevant to alopecia areata. Dr. Orlow has served on the board of Almirall, SA and R2 Technologies.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from Pfizer

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue